Literature DB >> 34651221

Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension.

Bi-Xi Chen1, Hai-Qun Xing2,3, Juan-Ni Gong4,5, Xiao-Juan Guo6, Xiao-Ying Xi1, Yuan-Hua Yang4,5, Li Huo2,3, Min-Fu Yang7.   

Abstract

PURPOSE: The aim of this study was to explore the association of cardiac fibroblast activation with clinical parameters and cardiovascular magnetic resonance (CMR) imaging parameters in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
METHODS: Thirteen CTEPH patients were prospectively enrolled. All of the patients underwent cardiac 68Gallium-labelled fibroblast activation protein inhibitor (68 Ga-FAPI-04)-positron emission tomography/computed tomography (PET/CT), right heart catheterisation, and echocardiography, and 11 of them additionally underwent CMR. Thirteen control subjects were selected to establish the normal range of cardiac 68 Ga-FAPI-04 uptake. Cardiac 68 Ga-FAPI-04 uptake higher than that in the blood pool was defined as abnormal. The global and segmental maximum standardised uptake values (SUVmax) of the right ventricle (RV) were measured and further expressed as target-to-background ratio (TBRRV) with left ventricular lateral wall activity as background. Late gadolinium enhancement (LGE) was visually evaluated, and native-T1 times, enhanced-T1 times, and extracellular volume (ECV) were quantitatively measured.
RESULTS: Ten CTEPH patients (77%) had abnormal 68 Ga-FAPI-04 uptake in RV, mainly located in the free wall, which was significantly higher than that in controls (TBRRV: 2.4 ± 0.9 vs 1.0 ± 0.1, P < 0.001). The TBRRV correlated positively with the thickness of RV wall (r = 0.815, P = 0.001) and inversely with RV fraction area change (RVFAC) (r =  - 0.804, P = 0.001) and tricuspid annular plane systolic excursion (TAPSE) (r =  - 0.678, P = 0.011). No correlation was found between 68 Ga-FAPI-04 activity and CMR imaging parameters.
CONCLUSION: Fibroblast activation in CTEPH, measured by 68 Ga-FAPI-04 imaging, is mainly localised in the RV free wall. Enhanced fibroblast activation reflects the thickening of the RV wall and decreased RV contractile function.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  68 Ga-FAPI-04; CMR; CTEPH; PET/CT

Mesh:

Substances:

Year:  2021        PMID: 34651221     DOI: 10.1007/s00259-021-05577-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

Review 1.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Right ventricular diastolic impairment in patients with pulmonary arterial hypertension.

Authors:  Silvia Rain; M Louis Handoko; Pia Trip; C Tji-Joong Gan; Nico Westerhof; Ger J Stienen; Walter J Paulus; Coen A C Ottenheijm; J Tim Marcus; Peter Dorfmüller; Christophe Guignabert; Marc Humbert; Peter Macdonald; Cris Dos Remedios; Piet E Postmus; Chandra Saripalli; Carlos G Hidalgo; Henk L Granzier; Anton Vonk-Noordegraaf; Jolanda van der Velden; Frances S de Man
Journal:  Circulation       Date:  2013-09-20       Impact factor: 29.690

3.  Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension.

Authors:  Pia Trip; Silvia Rain; M Louis Handoko; Cathelijne van der Bruggen; Harm J Bogaard; J Tim Marcus; Anco Boonstra; Nico Westerhof; Anton Vonk-Noordegraaf; Frances S de Man
Journal:  Eur Respir J       Date:  2015-04-16       Impact factor: 16.671

4.  Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.

Authors:  Marion Delcroix; Anton Vonk Noordegraaf; Elie Fadel; Irene Lang; Gérald Simonneau; Robert Naeije
Journal:  Eur Respir J       Date:  2012-08-16       Impact factor: 16.671

Review 5.  The emerging role of MRI in the diagnosis and management of cardiomyopathies.

Authors:  Carlos Eduardo Rochitte; Eduardo Marinho Tassi; Afonso Akio Shiozaki
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

6.  Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.

Authors:  Andrew S Flett; Martin P Hayward; Michael T Ashworth; Michael S Hansen; Andrew M Taylor; Perry M Elliott; Christopher McGregor; James C Moon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 7.  Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis.

Authors:  Marcello Disertori; Marta Rigoni; Nicola Pace; Giancarlo Casolo; Michela Masè; Lucio Gonzini; Donata Lucci; Giandomenico Nollo; Flavia Ravelli
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

8.  Impairment of Excitation-Contraction Coupling in Right Ventricular Hypertrophied Muscle with Fibrosis Induced by Pulmonary Artery Banding.

Authors:  Yoichiro Kusakari; Takashi Urashima; Daisuke Shimura; Erika Amemiya; Genki Miyasaka; Shunsuke Yokota; Yoshitaka Fujimoto; Toru Akaike; Takahiro Inoue; Susumu Minamisawa
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

9.  Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.

Authors:  Sairia Dass; Joseph J Suttie; Stefan K Piechnik; Vanessa M Ferreira; Cameron J Holloway; Rajarshi Banerjee; Masliza Mahmod; Lowri Cochlin; Theodoros D Karamitsos; Matthew D Robson; Hugh Watkins; Stefan Neubauer
Journal:  Circ Cardiovasc Imaging       Date:  2012-10-15       Impact factor: 7.792

10.  Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series).

Authors:  Kewal Asosingh; Serpil Erzurum
Journal:  Pulm Circ       Date:  2017-12-21       Impact factor: 3.017

View more
  4 in total

1.  Cardiac fibroblast activation imaging in a patient with hypertrophic cardiomyopathy.

Authors:  Yu Zhang; Yi-Lu Wang; Min-Fu Yang; Li Wang
Journal:  J Nucl Cardiol       Date:  2022-04-12       Impact factor: 5.952

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 3.  Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.

Authors:  Fawaz Alenezi; Taylor A Covington; Monica Mukherjee; Stephen C Mathai; Paul B Yu; Sudarshan Rajagopal
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

4.  Right Ventricle Remodeling in Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Jixiang Liu; Peiran Yang; Han Tian; Kaiyuan Zhen; Colm McCabe; Lan Zhao; Zhenguo Zhai
Journal:  J Transl Int Med       Date:  2022-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.